nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—peripheral nervous system neoplasm—sarcoma	0.727	1	CtDrD
Alitretinoin—CYP1A2—Dacarbazine—sarcoma	0.0218	0.243	CbGbCtD
Alitretinoin—ABCB1—Dactinomycin—sarcoma	0.0165	0.184	CbGbCtD
Alitretinoin—ABCB1—Mitoxantrone—sarcoma	0.0148	0.165	CbGbCtD
Alitretinoin—CYP1A2—Etoposide—sarcoma	0.0106	0.119	CbGbCtD
Alitretinoin—ABCB1—Vincristine—sarcoma	0.0102	0.114	CbGbCtD
Alitretinoin—ABCB1—Etoposide—sarcoma	0.00931	0.104	CbGbCtD
Alitretinoin—ABCB1—Doxorubicin—sarcoma	0.00635	0.0709	CbGbCtD
Alitretinoin—CRABP1—embryo—sarcoma	0.00187	0.0442	CbGeAlD
Alitretinoin—CRABP2—myometrium—sarcoma	0.00175	0.0416	CbGeAlD
Alitretinoin—RARA—mammary gland—sarcoma	0.0017	0.0402	CbGeAlD
Alitretinoin—CRABP2—embryo—sarcoma	0.00169	0.04	CbGeAlD
Alitretinoin—CRABP1—hematopoietic system—sarcoma	0.00167	0.0395	CbGeAlD
Alitretinoin—CRABP1—connective tissue—sarcoma	0.0016	0.038	CbGeAlD
Alitretinoin—CRABP2—seminal vesicle—sarcoma	0.00158	0.0376	CbGeAlD
Alitretinoin—CRABP2—connective tissue—sarcoma	0.00145	0.0344	CbGeAlD
Alitretinoin—CRABP1—skin of body—sarcoma	0.00145	0.0343	CbGeAlD
Alitretinoin—CRABP2—smooth muscle tissue—sarcoma	0.00133	0.0314	CbGeAlD
Alitretinoin—CRABP2—skin of body—sarcoma	0.00131	0.031	CbGeAlD
Alitretinoin—RARA—myometrium—sarcoma	0.0012	0.0285	CbGeAlD
Alitretinoin—CRABP1—tendon—sarcoma	0.0011	0.0261	CbGeAlD
Alitretinoin—RARG—hematopoietic system—sarcoma	0.0011	0.026	CbGeAlD
Alitretinoin—RARA—hematopoietic system—sarcoma	0.00103	0.0245	CbGeAlD
Alitretinoin—CRABP2—tendon—sarcoma	0.000997	0.0236	CbGeAlD
Alitretinoin—RARG—skin of body—sarcoma	0.000955	0.0226	CbGeAlD
Alitretinoin—RXRB—cardiac atrium—sarcoma	0.00094	0.0223	CbGeAlD
Alitretinoin—CRABP1—testis—sarcoma	0.000913	0.0216	CbGeAlD
Alitretinoin—RARB—tendon—sarcoma	0.000892	0.0211	CbGeAlD
Alitretinoin—RXRG—tendon—sarcoma	0.000871	0.0207	CbGeAlD
Alitretinoin—RARG—uterus—sarcoma	0.00083	0.0197	CbGeAlD
Alitretinoin—CRABP2—testis—sarcoma	0.000826	0.0196	CbGeAlD
Alitretinoin—RXRB—tendon—sarcoma	0.000819	0.0194	CbGeAlD
Alitretinoin—RARA—uterus—sarcoma	0.00078	0.0185	CbGeAlD
Alitretinoin—RXRA—liver—sarcoma	0.000777	0.0184	CbGeAlD
Alitretinoin—RARA—lymphoid tissue—sarcoma	0.000727	0.0172	CbGeAlD
Alitretinoin—RARG—tendon—sarcoma	0.000727	0.0172	CbGeAlD
Alitretinoin—RXRG—testis—sarcoma	0.000722	0.0171	CbGeAlD
Alitretinoin—RARB—liver—sarcoma	0.000698	0.0165	CbGeAlD
Alitretinoin—RARA—tendon—sarcoma	0.000684	0.0162	CbGeAlD
Alitretinoin—RXRB—testis—sarcoma	0.000678	0.0161	CbGeAlD
Alitretinoin—RARA—bone marrow—sarcoma	0.000662	0.0157	CbGeAlD
Alitretinoin—RXRB—liver—sarcoma	0.000641	0.0152	CbGeAlD
Alitretinoin—RARG—testis—sarcoma	0.000602	0.0143	CbGeAlD
Alitretinoin—RARA—testis—sarcoma	0.000566	0.0134	CbGeAlD
Alitretinoin—RARA—liver—sarcoma	0.000535	0.0127	CbGeAlD
Alitretinoin—RARB—lymph node—sarcoma	0.000535	0.0127	CbGeAlD
Alitretinoin—RARG—lymph node—sarcoma	0.000437	0.0103	CbGeAlD
Alitretinoin—RARA—lymph node—sarcoma	0.00041	0.00973	CbGeAlD
Alitretinoin—CYP1A2—hematopoietic system—sarcoma	0.000383	0.00908	CbGeAlD
Alitretinoin—ABCB1—myometrium—sarcoma	0.000229	0.00542	CbGeAlD
Alitretinoin—ABCB1—embryo—sarcoma	0.00022	0.00521	CbGeAlD
Alitretinoin—ABCB1—seminal vesicle—sarcoma	0.000207	0.00489	CbGeAlD
Alitretinoin—CYP1A2—liver—sarcoma	0.000198	0.0047	CbGeAlD
Alitretinoin—ABCB1—hematopoietic system—sarcoma	0.000196	0.00465	CbGeAlD
Alitretinoin—ABCB1—uterus—sarcoma	0.000148	0.00351	CbGeAlD
Alitretinoin—ABCB1—lymphoid tissue—sarcoma	0.000138	0.00327	CbGeAlD
Alitretinoin—ABCB1—bone marrow—sarcoma	0.000126	0.00298	CbGeAlD
Alitretinoin—ABCB1—testis—sarcoma	0.000108	0.00255	CbGeAlD
Alitretinoin—ABCB1—liver—sarcoma	0.000102	0.00241	CbGeAlD
Alitretinoin—ABCB1—lymph node—sarcoma	7.8e-05	0.00185	CbGeAlD
Alitretinoin—Pollakiuria—Epirubicin—sarcoma	7.74e-05	0.00055	CcSEcCtD
Alitretinoin—Hypersensitivity—Vincristine—sarcoma	7.73e-05	0.000549	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Epirubicin—sarcoma	7.64e-05	0.000543	CcSEcCtD
Alitretinoin—Paraesthesia—Etoposide—sarcoma	7.63e-05	0.000542	CcSEcCtD
Alitretinoin—Weight increased—Epirubicin—sarcoma	7.62e-05	0.000541	CcSEcCtD
Alitretinoin—Pancreatitis—Doxorubicin—sarcoma	7.6e-05	0.00054	CcSEcCtD
Alitretinoin—Weight decreased—Epirubicin—sarcoma	7.58e-05	0.000538	CcSEcCtD
Alitretinoin—Dyspnoea—Etoposide—sarcoma	7.57e-05	0.000538	CcSEcCtD
Alitretinoin—Somnolence—Etoposide—sarcoma	7.55e-05	0.000537	CcSEcCtD
Alitretinoin—Hypersensitivity—Mitoxantrone—sarcoma	7.53e-05	0.000535	CcSEcCtD
Alitretinoin—Asthenia—Vincristine—sarcoma	7.53e-05	0.000535	CcSEcCtD
Alitretinoin—Vomiting—Thiotepa—sarcoma	7.52e-05	0.000534	CcSEcCtD
Alitretinoin—Pneumonia—Epirubicin—sarcoma	7.51e-05	0.000534	CcSEcCtD
Alitretinoin—Infestation NOS—Epirubicin—sarcoma	7.47e-05	0.000531	CcSEcCtD
Alitretinoin—Drowsiness—Epirubicin—sarcoma	7.47e-05	0.000531	CcSEcCtD
Alitretinoin—Infestation—Epirubicin—sarcoma	7.47e-05	0.000531	CcSEcCtD
Alitretinoin—Vomiting—Dactinomycin—sarcoma	7.46e-05	0.00053	CcSEcCtD
Alitretinoin—Rash—Thiotepa—sarcoma	7.46e-05	0.00053	CcSEcCtD
Alitretinoin—Dermatitis—Thiotepa—sarcoma	7.45e-05	0.000529	CcSEcCtD
Alitretinoin—Headache—Thiotepa—sarcoma	7.41e-05	0.000526	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Epirubicin—sarcoma	7.4e-05	0.000526	CcSEcCtD
Alitretinoin—Rash—Dactinomycin—sarcoma	7.4e-05	0.000526	CcSEcCtD
Alitretinoin—Decreased appetite—Etoposide—sarcoma	7.39e-05	0.000525	CcSEcCtD
Alitretinoin—Renal failure—Epirubicin—sarcoma	7.34e-05	0.000521	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Etoposide—sarcoma	7.34e-05	0.000521	CcSEcCtD
Alitretinoin—Asthenia—Mitoxantrone—sarcoma	7.33e-05	0.000521	CcSEcCtD
Alitretinoin—Fatigue—Etoposide—sarcoma	7.33e-05	0.00052	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Epirubicin—sarcoma	7.32e-05	0.00052	CcSEcCtD
Alitretinoin—Stomatitis—Epirubicin—sarcoma	7.28e-05	0.000517	CcSEcCtD
Alitretinoin—Constipation—Etoposide—sarcoma	7.27e-05	0.000516	CcSEcCtD
Alitretinoin—Pain—Etoposide—sarcoma	7.27e-05	0.000516	CcSEcCtD
Alitretinoin—Urinary tract infection—Epirubicin—sarcoma	7.26e-05	0.000516	CcSEcCtD
Alitretinoin—Conjunctivitis—Epirubicin—sarcoma	7.26e-05	0.000516	CcSEcCtD
Alitretinoin—Neutropenia—Doxorubicin—sarcoma	7.25e-05	0.000515	CcSEcCtD
Alitretinoin—Dysuria—Doxorubicin—sarcoma	7.25e-05	0.000515	CcSEcCtD
Alitretinoin—Upper respiratory tract infection—Doxorubicin—sarcoma	7.2e-05	0.000512	CcSEcCtD
Alitretinoin—Diarrhoea—Vincristine—sarcoma	7.18e-05	0.00051	CcSEcCtD
Alitretinoin—Sweating—Epirubicin—sarcoma	7.16e-05	0.000509	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—sarcoma	7.16e-05	0.000509	CcSEcCtD
Alitretinoin—Haematuria—Epirubicin—sarcoma	7.12e-05	0.000506	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Doxorubicin—sarcoma	7.07e-05	0.000503	CcSEcCtD
Alitretinoin—Weight increased—Doxorubicin—sarcoma	7.05e-05	0.000501	CcSEcCtD
Alitretinoin—Epistaxis—Epirubicin—sarcoma	7.04e-05	0.0005	CcSEcCtD
Alitretinoin—Nausea—Thiotepa—sarcoma	7.03e-05	0.000499	CcSEcCtD
Alitretinoin—Weight decreased—Doxorubicin—sarcoma	7.01e-05	0.000498	CcSEcCtD
Alitretinoin—Sinusitis—Epirubicin—sarcoma	7.01e-05	0.000498	CcSEcCtD
Alitretinoin—Feeling abnormal—Etoposide—sarcoma	7e-05	0.000497	CcSEcCtD
Alitretinoin—Diarrhoea—Mitoxantrone—sarcoma	6.99e-05	0.000497	CcSEcCtD
Alitretinoin—Nausea—Dactinomycin—sarcoma	6.97e-05	0.000495	CcSEcCtD
Alitretinoin—Agranulocytosis—Epirubicin—sarcoma	6.97e-05	0.000495	CcSEcCtD
Alitretinoin—Pneumonia—Doxorubicin—sarcoma	6.95e-05	0.000494	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Etoposide—sarcoma	6.95e-05	0.000494	CcSEcCtD
Alitretinoin—Dizziness—Vincristine—sarcoma	6.94e-05	0.000493	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—sarcoma	6.91e-05	0.000491	CcSEcCtD
Alitretinoin—Infestation—Doxorubicin—sarcoma	6.91e-05	0.000491	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—sarcoma	6.91e-05	0.000491	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—sarcoma	6.85e-05	0.000487	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—sarcoma	6.79e-05	0.000483	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Doxorubicin—sarcoma	6.77e-05	0.000481	CcSEcCtD
Alitretinoin—Urticaria—Etoposide—sarcoma	6.75e-05	0.00048	CcSEcCtD
Alitretinoin—Haemoglobin—Epirubicin—sarcoma	6.74e-05	0.000479	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—sarcoma	6.74e-05	0.000478	CcSEcCtD
Alitretinoin—Abdominal pain—Etoposide—sarcoma	6.72e-05	0.000477	CcSEcCtD
Alitretinoin—Body temperature increased—Etoposide—sarcoma	6.72e-05	0.000477	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—sarcoma	6.72e-05	0.000477	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—sarcoma	6.72e-05	0.000477	CcSEcCtD
Alitretinoin—Haemorrhage—Epirubicin—sarcoma	6.7e-05	0.000476	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—sarcoma	6.7e-05	0.000476	CcSEcCtD
Alitretinoin—Hypoaesthesia—Epirubicin—sarcoma	6.67e-05	0.000474	CcSEcCtD
Alitretinoin—Vomiting—Vincristine—sarcoma	6.67e-05	0.000474	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—sarcoma	6.65e-05	0.000473	CcSEcCtD
Alitretinoin—Sweating—Doxorubicin—sarcoma	6.62e-05	0.000471	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—sarcoma	6.62e-05	0.00047	CcSEcCtD
Alitretinoin—Rash—Vincristine—sarcoma	6.61e-05	0.00047	CcSEcCtD
Alitretinoin—Dermatitis—Vincristine—sarcoma	6.61e-05	0.000469	CcSEcCtD
Alitretinoin—Oedema peripheral—Epirubicin—sarcoma	6.6e-05	0.000469	CcSEcCtD
Alitretinoin—Haematuria—Doxorubicin—sarcoma	6.59e-05	0.000468	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—sarcoma	6.57e-05	0.000467	CcSEcCtD
Alitretinoin—Headache—Vincristine—sarcoma	6.57e-05	0.000467	CcSEcCtD
Alitretinoin—Epistaxis—Doxorubicin—sarcoma	6.52e-05	0.000463	CcSEcCtD
Alitretinoin—Vomiting—Mitoxantrone—sarcoma	6.49e-05	0.000461	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—sarcoma	6.48e-05	0.000461	CcSEcCtD
Alitretinoin—Visual impairment—Epirubicin—sarcoma	6.46e-05	0.000459	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—sarcoma	6.45e-05	0.000458	CcSEcCtD
Alitretinoin—Rash—Mitoxantrone—sarcoma	6.44e-05	0.000458	CcSEcCtD
Alitretinoin—Dermatitis—Mitoxantrone—sarcoma	6.43e-05	0.000457	CcSEcCtD
Alitretinoin—Headache—Mitoxantrone—sarcoma	6.4e-05	0.000455	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—sarcoma	6.34e-05	0.00045	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—sarcoma	6.26e-05	0.000445	CcSEcCtD
Alitretinoin—Hypersensitivity—Etoposide—sarcoma	6.26e-05	0.000445	CcSEcCtD
Alitretinoin—Tinnitus—Epirubicin—sarcoma	6.25e-05	0.000444	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—sarcoma	6.23e-05	0.000443	CcSEcCtD
Alitretinoin—Nausea—Vincristine—sarcoma	6.23e-05	0.000443	CcSEcCtD
Alitretinoin—Flushing—Epirubicin—sarcoma	6.22e-05	0.000442	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—sarcoma	6.2e-05	0.000441	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—sarcoma	6.2e-05	0.000441	CcSEcCtD
Alitretinoin—Hypoaesthesia—Doxorubicin—sarcoma	6.17e-05	0.000438	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—sarcoma	6.16e-05	0.000437	CcSEcCtD
Alitretinoin—Urinary tract disorder—Doxorubicin—sarcoma	6.13e-05	0.000435	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—sarcoma	6.11e-05	0.000434	CcSEcCtD
Alitretinoin—Asthenia—Etoposide—sarcoma	6.1e-05	0.000433	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—sarcoma	6.08e-05	0.000432	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—sarcoma	6.08e-05	0.000432	CcSEcCtD
Alitretinoin—Nausea—Mitoxantrone—sarcoma	6.07e-05	0.000431	CcSEcCtD
Alitretinoin—Chills—Epirubicin—sarcoma	6.01e-05	0.000427	CcSEcCtD
Alitretinoin—Pruritus—Etoposide—sarcoma	6.01e-05	0.000427	CcSEcCtD
Alitretinoin—Arrhythmia—Epirubicin—sarcoma	5.99e-05	0.000425	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—sarcoma	5.98e-05	0.000425	CcSEcCtD
Alitretinoin—Alopecia—Epirubicin—sarcoma	5.92e-05	0.000421	CcSEcCtD
Alitretinoin—Mental disorder—Epirubicin—sarcoma	5.87e-05	0.000417	CcSEcCtD
Alitretinoin—Erythema multiforme—Doxorubicin—sarcoma	5.86e-05	0.000417	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—sarcoma	5.84e-05	0.000415	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—sarcoma	5.84e-05	0.000415	CcSEcCtD
Alitretinoin—Diarrhoea—Etoposide—sarcoma	5.81e-05	0.000413	CcSEcCtD
Alitretinoin—Eye disorder—Doxorubicin—sarcoma	5.8e-05	0.000412	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—sarcoma	5.78e-05	0.000411	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—sarcoma	5.76e-05	0.000409	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—sarcoma	5.75e-05	0.000409	CcSEcCtD
Alitretinoin—Tension—Epirubicin—sarcoma	5.73e-05	0.000407	CcSEcCtD
Alitretinoin—Nervousness—Epirubicin—sarcoma	5.67e-05	0.000403	CcSEcCtD
Alitretinoin—Back pain—Epirubicin—sarcoma	5.64e-05	0.000401	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—sarcoma	5.63e-05	0.0004	CcSEcCtD
Alitretinoin—Dizziness—Etoposide—sarcoma	5.62e-05	0.000399	CcSEcCtD
Alitretinoin—Chills—Doxorubicin—sarcoma	5.57e-05	0.000395	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—sarcoma	5.54e-05	0.000394	CcSEcCtD
Alitretinoin—Vision blurred—Epirubicin—sarcoma	5.5e-05	0.000391	CcSEcCtD
Alitretinoin—Alopecia—Doxorubicin—sarcoma	5.48e-05	0.000389	CcSEcCtD
Alitretinoin—Mental disorder—Doxorubicin—sarcoma	5.43e-05	0.000386	CcSEcCtD
Alitretinoin—Ill-defined disorder—Epirubicin—sarcoma	5.41e-05	0.000385	CcSEcCtD
Alitretinoin—Vomiting—Etoposide—sarcoma	5.4e-05	0.000384	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—sarcoma	5.4e-05	0.000384	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—sarcoma	5.4e-05	0.000384	CcSEcCtD
Alitretinoin—Anaemia—Epirubicin—sarcoma	5.39e-05	0.000383	CcSEcCtD
Alitretinoin—Agitation—Epirubicin—sarcoma	5.36e-05	0.000381	CcSEcCtD
Alitretinoin—Rash—Etoposide—sarcoma	5.36e-05	0.000381	CcSEcCtD
Alitretinoin—Dermatitis—Etoposide—sarcoma	5.35e-05	0.00038	CcSEcCtD
Alitretinoin—Headache—Etoposide—sarcoma	5.32e-05	0.000378	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—sarcoma	5.32e-05	0.000378	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—sarcoma	5.3e-05	0.000376	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—sarcoma	5.26e-05	0.000374	CcSEcCtD
Alitretinoin—Nervousness—Doxorubicin—sarcoma	5.24e-05	0.000373	CcSEcCtD
Alitretinoin—Syncope—Epirubicin—sarcoma	5.23e-05	0.000372	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—sarcoma	5.22e-05	0.000371	CcSEcCtD
Alitretinoin—Palpitations—Epirubicin—sarcoma	5.16e-05	0.000366	CcSEcCtD
Alitretinoin—Loss of consciousness—Epirubicin—sarcoma	5.13e-05	0.000364	CcSEcCtD
Alitretinoin—Cough—Epirubicin—sarcoma	5.09e-05	0.000362	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—sarcoma	5.09e-05	0.000362	CcSEcCtD
Alitretinoin—Convulsion—Epirubicin—sarcoma	5.06e-05	0.000359	CcSEcCtD
Alitretinoin—Nausea—Etoposide—sarcoma	5.05e-05	0.000359	CcSEcCtD
Alitretinoin—Hypertension—Epirubicin—sarcoma	5.04e-05	0.000358	CcSEcCtD
Alitretinoin—Ill-defined disorder—Doxorubicin—sarcoma	5.01e-05	0.000356	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—sarcoma	4.99e-05	0.000355	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—sarcoma	4.97e-05	0.000353	CcSEcCtD
Alitretinoin—Chest pain—Epirubicin—sarcoma	4.97e-05	0.000353	CcSEcCtD
Alitretinoin—Arthralgia—Epirubicin—sarcoma	4.97e-05	0.000353	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—sarcoma	4.96e-05	0.000353	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—sarcoma	4.95e-05	0.000352	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.93e-05	0.000351	CcSEcCtD
Alitretinoin—Discomfort—Epirubicin—sarcoma	4.91e-05	0.000349	CcSEcCtD
Alitretinoin—Malaise—Doxorubicin—sarcoma	4.87e-05	0.000346	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—sarcoma	4.86e-05	0.000345	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—sarcoma	4.84e-05	0.000344	CcSEcCtD
Alitretinoin—Confusional state—Epirubicin—sarcoma	4.8e-05	0.000341	CcSEcCtD
Alitretinoin—Palpitations—Doxorubicin—sarcoma	4.77e-05	0.000339	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—sarcoma	4.76e-05	0.000338	CcSEcCtD
Alitretinoin—Anaphylactic shock—Epirubicin—sarcoma	4.76e-05	0.000338	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—sarcoma	4.75e-05	0.000337	CcSEcCtD
Alitretinoin—Infection—Epirubicin—sarcoma	4.73e-05	0.000336	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—sarcoma	4.71e-05	0.000335	CcSEcCtD
Alitretinoin—Shock—Epirubicin—sarcoma	4.69e-05	0.000333	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—sarcoma	4.68e-05	0.000332	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—sarcoma	4.67e-05	0.000332	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—sarcoma	4.66e-05	0.000331	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—sarcoma	4.66e-05	0.000331	CcSEcCtD
Alitretinoin—Tachycardia—Epirubicin—sarcoma	4.65e-05	0.00033	CcSEcCtD
Alitretinoin—Skin disorder—Epirubicin—sarcoma	4.63e-05	0.000329	CcSEcCtD
Alitretinoin—Hyperhidrosis—Epirubicin—sarcoma	4.6e-05	0.000327	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—sarcoma	4.6e-05	0.000327	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—sarcoma	4.6e-05	0.000327	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—sarcoma	4.6e-05	0.000327	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—sarcoma	4.58e-05	0.000325	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.57e-05	0.000324	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—sarcoma	4.54e-05	0.000323	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—sarcoma	4.54e-05	0.000323	CcSEcCtD
Alitretinoin—Dry mouth—Doxorubicin—sarcoma	4.5e-05	0.000319	CcSEcCtD
Alitretinoin—Hypotension—Epirubicin—sarcoma	4.45e-05	0.000316	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—sarcoma	4.44e-05	0.000316	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—sarcoma	4.41e-05	0.000313	CcSEcCtD
Alitretinoin—Oedema—Doxorubicin—sarcoma	4.41e-05	0.000313	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—sarcoma	4.38e-05	0.000311	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—sarcoma	4.34e-05	0.000308	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—sarcoma	4.34e-05	0.000308	CcSEcCtD
Alitretinoin—Nervous system disorder—Doxorubicin—sarcoma	4.32e-05	0.000307	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—sarcoma	4.31e-05	0.000307	CcSEcCtD
Alitretinoin—Insomnia—Epirubicin—sarcoma	4.31e-05	0.000306	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—sarcoma	4.3e-05	0.000306	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—sarcoma	4.28e-05	0.000304	CcSEcCtD
Alitretinoin—Paraesthesia—Epirubicin—sarcoma	4.28e-05	0.000304	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—sarcoma	4.26e-05	0.000303	CcSEcCtD
Alitretinoin—Dyspnoea—Epirubicin—sarcoma	4.25e-05	0.000302	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—sarcoma	4.23e-05	0.000301	CcSEcCtD
Alitretinoin—Anorexia—Doxorubicin—sarcoma	4.2e-05	0.000298	CcSEcCtD
Alitretinoin—Dyspepsia—Epirubicin—sarcoma	4.19e-05	0.000298	CcSEcCtD
Alitretinoin—Decreased appetite—Epirubicin—sarcoma	4.14e-05	0.000294	CcSEcCtD
Alitretinoin—Hypotension—Doxorubicin—sarcoma	4.12e-05	0.000293	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—sarcoma	4.11e-05	0.000292	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—sarcoma	4.11e-05	0.000292	CcSEcCtD
Alitretinoin—Constipation—Epirubicin—sarcoma	4.07e-05	0.000289	CcSEcCtD
Alitretinoin—Pain—Epirubicin—sarcoma	4.07e-05	0.000289	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—sarcoma	4.01e-05	0.000285	CcSEcCtD
Alitretinoin—Insomnia—Doxorubicin—sarcoma	3.99e-05	0.000283	CcSEcCtD
Alitretinoin—Paraesthesia—Doxorubicin—sarcoma	3.96e-05	0.000281	CcSEcCtD
Alitretinoin—Dyspnoea—Doxorubicin—sarcoma	3.93e-05	0.000279	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—sarcoma	3.92e-05	0.000279	CcSEcCtD
Alitretinoin—Somnolence—Doxorubicin—sarcoma	3.92e-05	0.000278	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Epirubicin—sarcoma	3.89e-05	0.000277	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—sarcoma	3.88e-05	0.000276	CcSEcCtD
Alitretinoin—Decreased appetite—Doxorubicin—sarcoma	3.83e-05	0.000272	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—sarcoma	3.8e-05	0.00027	CcSEcCtD
Alitretinoin—Fatigue—Doxorubicin—sarcoma	3.8e-05	0.00027	CcSEcCtD
Alitretinoin—Urticaria—Epirubicin—sarcoma	3.78e-05	0.000269	CcSEcCtD
Alitretinoin—Pain—Doxorubicin—sarcoma	3.77e-05	0.000268	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—sarcoma	3.77e-05	0.000268	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—sarcoma	3.76e-05	0.000267	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—sarcoma	3.76e-05	0.000267	CcSEcCtD
Alitretinoin—Feeling abnormal—Doxorubicin—sarcoma	3.63e-05	0.000258	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Doxorubicin—sarcoma	3.6e-05	0.000256	CcSEcCtD
Alitretinoin—Hypersensitivity—Epirubicin—sarcoma	3.51e-05	0.000249	CcSEcCtD
Alitretinoin—Urticaria—Doxorubicin—sarcoma	3.5e-05	0.000249	CcSEcCtD
Alitretinoin—Abdominal pain—Doxorubicin—sarcoma	3.48e-05	0.000247	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—sarcoma	3.48e-05	0.000247	CcSEcCtD
Alitretinoin—Asthenia—Epirubicin—sarcoma	3.42e-05	0.000243	CcSEcCtD
Alitretinoin—Pruritus—Epirubicin—sarcoma	3.37e-05	0.000239	CcSEcCtD
Alitretinoin—Diarrhoea—Epirubicin—sarcoma	3.26e-05	0.000231	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—sarcoma	3.25e-05	0.000231	CcSEcCtD
Alitretinoin—Asthenia—Doxorubicin—sarcoma	3.16e-05	0.000225	CcSEcCtD
Alitretinoin—Dizziness—Epirubicin—sarcoma	3.15e-05	0.000224	CcSEcCtD
Alitretinoin—Pruritus—Doxorubicin—sarcoma	3.12e-05	0.000221	CcSEcCtD
Alitretinoin—Vomiting—Epirubicin—sarcoma	3.03e-05	0.000215	CcSEcCtD
Alitretinoin—Diarrhoea—Doxorubicin—sarcoma	3.02e-05	0.000214	CcSEcCtD
Alitretinoin—Rash—Epirubicin—sarcoma	3e-05	0.000213	CcSEcCtD
Alitretinoin—Dermatitis—Epirubicin—sarcoma	3e-05	0.000213	CcSEcCtD
Alitretinoin—Headache—Epirubicin—sarcoma	2.98e-05	0.000212	CcSEcCtD
Alitretinoin—Dizziness—Doxorubicin—sarcoma	2.91e-05	0.000207	CcSEcCtD
Alitretinoin—Nausea—Epirubicin—sarcoma	2.83e-05	0.000201	CcSEcCtD
Alitretinoin—Vomiting—Doxorubicin—sarcoma	2.8e-05	0.000199	CcSEcCtD
Alitretinoin—Rash—Doxorubicin—sarcoma	2.78e-05	0.000197	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—sarcoma	2.78e-05	0.000197	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—sarcoma	2.76e-05	0.000196	CcSEcCtD
Alitretinoin—Nausea—Doxorubicin—sarcoma	2.62e-05	0.000186	CcSEcCtD
